Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

Blood

Volumn 100, Issue 8, 2002, Pages 3037-3040

  Juszczynski, Przemyslaw ^a,b   Kalinka, Ewa ^a,b   Bienvenu, Jacques ^a,b   Woszczek, Grzegorz ^a,b   Borowiec, Maciej ^a,b   Robak, Tadeusz ^a,b   Kowalski, Marek ^a,b   Lech Maranda, Ewa ^a,b   Baseggio, Lucile ^a,b   Coiffier, Bertrand ^a,b   Salles, Gilles ^a,b   Warzocha, Krzysztof ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; LYMPHOTOXIN; PREDNISOLONE; PREDNISONE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HLA SYSTEM; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; NULL ALLELE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 18644374724     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0654     Document Type: Article

References (23)

1. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508-511.
2. Westendorp RGJ, Langermans JAM, Huizinga TWJ, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170-173.
3. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLAA1, B8 and DR3 alleles. J Exp Med. 1993; 177:557-560.
4. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphism in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scan J Immunol. 1996;43:456-463.
5. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990;87: 1233-1237.
6. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993;23:224-231.
7. Brinkman BM, Huizinga TW, Kurban SS, et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol. 1997;36:516-521.
8. Verjans GM, Brinkman BM, Van Doornik CE, Kijlstra A, Verweij CL. Polymorphism of tumor necrosis factor-alpha (TNFα) at position-308 in relation to ankylosing spondylitis. Clin Exp Immunol. 1994;97:45-47.
9. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 1996;2:405-411.
10. Garcia-Merino A, Alper CA, Usuku K, et al. Tumor necrosis factor (TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to disease associated with the major histocompatibility complex and TNF secretion. Hum Immunol. 1996;50:11-21.
11. Peruccio D, D'Alfonso S, Borelli I, et al. Distribution of tumor necrosis factor alleles (Ncol RFLP) and their relationship to HLA haplotypes in an Italian population. Hum Hered. 1993;43:103-110.
12. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC haplotypes affect the activity of tumor necrosis factor alpha. Clin Exp Immunol. 1993; 92:14-18.
13. Cox A, Gonzalez AM, Wilson AG, et al. Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. Diabetologia. 1994;37:500-503.
14. Brinkman BMN, Keet IPM, Miedema F, Verweij CL, Klein MR. Polymorphisms within the human tumor necrosis factor-α promoter region in human immunodeficiency virus type 1-seropositive persons. J Infect Dis. 1997;175:188-190.
15. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943-3948.
16. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3199.
17. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993;16:180-186.
18. Takashiba S, Shapira L,Amar S, Van Dyke TE. Cloning and characterization of human TNFα promoter region. Gene. 1993;131:307-308.
19. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
20. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018-1026.
21. Dorak MT, Lawson T, Machulla HKG, Darke C, Mills KI, Burnett AK. Unravelling an HLA-DR as. sociation in childhood acute lymphoblastic leukemia. Blood. 1999;94:694-700.
22. The International Non-Hodgkin's Lymphoma Project: a predictive model for aggressive non-Hodgkin lymphoma. N Engl J Med. 1993;329: 987-994.
23. Caligaris-Cappio F. How immunology is reshaping clinical disciplines: the example of haematol. ogy. Lancet. 2001;358:49-55.